Used primarily in pharmaceutical research as a potent and selective inhibitor of specific protein degradation pathways, particularly targeting E3 ubiquitin ligases. It functions as a molecular glue or PROTAC (proteolysis-targeting chimera) component, enabling targeted degradation of disease-related proteins. This makes it valuable in oncology research, especially in developing therapies for hematological cancers such as multiple myeloma. Its structure allows efficient binding to cereblon (CRBN), a key protein in the ubiquitin-proteasome system, promoting the degradation of transcription factors like Ikaros and Aiolos. Due to its blood-brain barrier permeability and metabolic stability, it is also explored in neurological disorders and inflammatory conditions. Commonly used in preclinical studies to evaluate targeted protein degradation efficacy and optimize drug design in precision medicine.